Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thymus Neoplasms × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 57 Carcinoma, Renal Cell 33 Neoplasm Metastasis 31 Neoplasms 21 Neuroendocrine Tumors 17 Kidney Neoplasms 17 Prostatic Neoplasms 15 Recurrence 14 Head and Neck Neoplasms 13 Hodgkin Disease 11 Tuberous Sclerosis 10 Triple Negative Breast Neoplasms 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, Mantle-Cell 10 Multiple Myeloma 9 Lymphoma, Large B-Cell, Diffuse 9 Colorectal Neoplasms 9 Brain Neoplasms 9 Waldenstrom Macroglobulinemia 8 Sarcoma 8 Pancreatic Neoplasms 8 Lymphoma 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Glioblastoma 8 Melanoma 7 Lymphoma, Follicular 7 Glioma 7 Carcinoma, Non-Small-Cell Lung 7 Carcinoma, Neuroendocrine 7 Stomach Neoplasms 6

Interventions

Drug Therapy 2 Blood Specimen Collection 2 ribociclib 1 pembrolizumab 1 palbociclib 1 epacadostat 1 bosutinib 1 amrubicin 1 Tumor Burden 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Quality of Life 1 Proton Therapy 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1 Histocompatibility Testing 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Everolimus 1 Erlotinib Hydrochloride 1 Cisplatin 1 Bevacizumab 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡